Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT).

Li, Susan; Ozguroglu, Mustafa; Luna, Yesenia; Mundle, Suneel; Chi, Kim N.; Fizazi, Karim; Namphuong Tran, Namphuong Tran; Fein, Luis Enrique; Matsubara, Nobuaki; Antolin, Alfredo Rodriguez; Ye, Dingwei; Feyerabend, Susan; Protheroe, Andrew; Sulur, Giri

dc.contributor.author	Li, Susan
dc.contributor.author	Ozguroglu, Mustafa
dc.contributor.author	Luna, Yesenia
dc.contributor.author	Mundle, Suneel
dc.contributor.author	Chi, Kim N.
dc.contributor.author	Fizazi, Karim
dc.contributor.author	Namphuong Tran, Namphuong Tran
dc.contributor.author	Fein, Luis Enrique
dc.contributor.author	Matsubara, Nobuaki
dc.contributor.author	Antolin, Alfredo Rodriguez
dc.contributor.author	Ye, Dingwei
dc.contributor.author	Feyerabend, Susan
dc.contributor.author	Protheroe, Andrew
dc.contributor.author	Sulur, Giri
dc.date.accessioned	2021-03-03T08:23:05Z
dc.date.available	2021-03-03T08:23:05Z
dc.identifier.citation	Fizazi K., Namphuong Tran N. T. , Fein L. E. , Matsubara N., Antolin A. R. , Ozguroglu M., Ye D., Feyerabend S., Protheroe A., Sulur G., et al., "Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT).", ASCO-SITC Clinical Immuno-Oncology Symposium, San-Francisco, Kostarika, 28 Şubat - 02 Mart 2019, cilt.37
dc.identifier.other	vv_1032021
dc.identifier.other	av_173a8158-9bbf-4ebc-ad9e-f8f11cdeccf1
dc.identifier.uri	http://hdl.handle.net/20.500.12627/20969
dc.identifier.uri	https://doi.org/10.1200/jco.2019.37.7_suppl.141
dc.language.iso	eng
dc.subject	Dahili Tıp Bilimleri
dc.subject	İç Hastalıkları
dc.subject	Onkoloji
dc.subject	Klinik Tıp (MED)
dc.subject	Tıp
dc.subject	Sağlık Bilimleri
dc.subject	Klinik Tıp
dc.subject	ONKOLOJİ
dc.title	Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate plus prednisone (AA plus P) added to androgen deprivation therapy (ADT).
dc.type	Bildiri
dc.contributor.department	, ,
dc.identifier.volume	37
dc.contributor.firstauthorID	263206

Files in this item

Files	Size	Format	View
There are no files associated with this item.

This item appears in the following Collection(s)

Bildiri [64839]

Show simple item record